AnaptysBio reports Q2 FY26 results; Jemperli and Quimilza milestones flagged
AnaptysBio reported Q2 FY26 results. It said Jemperli is showing year-over-year growth, with potential FDA actions and a litigation judgment expected within 6 months. The company also said it expects an FDA decision for Quimilza in December 2026.
AnaptysBio reported Q2 FY26 results and said Jemperli shows YoY growth. The company said potential FDA actions and a litigation judgment are expected within 6 months, and the Quimilza FDA decision is due in Dec. 2026.